Andrew Moreo, provides daily control as well as strategic guidance for the process development. He ensures that all activities within the process development and preclinical manufacturing teams. He ensures that all activities within the process development are within compliance standards. Mr. Moreo has over 20 years of experience in genetic and molecular research. He has worked for RINCH for the past 13 years focusing on AAV including the development of the current AAV production platform. Mr. Moreo has a BS in Biology from Purdue University
Also Speaking
Also Speaking
Investor List
Take a look at some of the investors who attended Advanced Therapies Week 2023.
6 January 2023